Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2024-194857

Published: 2024

Journal Articles

The Impact of Air Pollutants on a Chicagoland Cohort of Patients with Acute Myeloid Leukemia

Andrew Palmer, Garth Rauscher, Ivy Abraham, Madelyn Burkart, Ami Dave, Nepheli Raptis, Ahmed Aleem, Vedavyas Gannamani, Amani Erra, Sarah Monick, Carlos Galvez, Melissa L. Larson, Maryam Zia, Stephanie B. Tsai, Jessica K. Altman, Wendy Stock, Irum Khan, Anand Ashwin Patel

Blood (2023) 142 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2023-178265

Published: 2023

Journal Articles

A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic

Megan Randall, Chen Zhang, Matthew Kroll, Kelsey Pandrangi, Gautham Prakash, Cherry Au, Ashley Dunton, Yanyu Zhang, Melissa L. Larson, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 12288–12289.

https://doi.org/10.1182/blood-2022-167402

Published: 2022

Journal Articles

Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML

Ivy Abraham, Garth Rauscher, Anand Ashwin Patel, Sarah Monick, Madelyn Burkhart, Eshana Shah, Ami Dave, Matthew Kroll, Stephanie B. Tsai, Stephanie Berg, Amani Erra, Vedavyas Gannamani, Maryam Zia, Melissa L. Larson, Wendy Stock, Jessica K. Altman, Irum Khan

Blood (2022) 140 (Supplement 1): 6061–6063.

https://doi.org/10.1182/blood-2022-166907

Published: 2022

Journal Articles

Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Blood (2022) 139 (14): 2212–2226.

https://doi.org/10.1182/blood.2021012830

Published: 2022

Includes: Supplemental data

Journal Articles

Structural and Social Barriers to Survival in Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML)

Madelyn Burkart, Ivy Abraham, Garth Rauscher, Nepheli Raptis, Maryam Zia, Anand Ashwin Patel, Ami Dave, Stephanie Berg, Wendy Stock, Melissa L. Larson, William B Pearse, Jessica K. Altman, Irum Khan, Shira Dinner

Blood (2021) 138 (Supplement 1): 844.

https://doi.org/10.1182/blood-2021-151677

Published: 2021

Journal Articles

The Impact of Non-Clinical Factors in Clinical Trial Enrollments of Patients with Hematologic Malignancies

Jamile M. Shammo, Anne Timmermann, Deborah A. Katz, Agne Paner, Seo-Hyun Kim, Irene dehghan-Paz, Melissa L. Larson, Parameswaran Venugopal, Celalettin Ustun, Ankur Varma, Sunita Nathan

Blood (2021) 138 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2021-148135

Published: 2021

Journal Articles

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Blood (2020) 136 (Supplement 1): 58–59.

https://doi.org/10.1182/blood-2020-135929

Published: 2020

Journal Articles

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Ivy Abraham, MD, Garth Rauscher, PhD MPH, Anand Ashwin Patel, MD, Wendy Stock, MD, Maryam Zia, MD, Sushma Bharadwaj, MD, Koosha Paydary, MD, Maria Acevedo-Mendez, John P Galvin, MDMS,MPH, William Pearse, MD, Jessica K. Altman, John G. Quigley, Priya Rajakumar, MD, Melissa L. Larson, MD, Irum Khan, MD

Blood (2019) 134 (Supplement_1): 3413.

https://doi.org/10.1182/blood-2019-124974

Published: 2019

Journal Articles

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Gail J. Roboz, MD, Melissa L. Larson, MD, S. Eric Rubenstein, MD, Scott R Solomon, MD, Gary J. Schiller, MD, Qi An, Emaryn Mancino, Michael Chiarella, Arthur C. Louie, Tara L Lin, MD

Blood (2018) 132 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2018-99-111537

Published: 2018

Journal Articles

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

Jacqueline Baptista, RN, APN, Eris Tollkuci, PharmD, Sunita Nathan, MD, John J. Maciejewski, MD PhD, Melissa L. Larson, MD, Gorgun Akpek, MD MHS

Blood (2016) 128 (22): 5200.

https://doi.org/10.1182/blood.V128.22.5200.5200

Published: 2016

Journal Articles

A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS

Jamile M. Shammo, MD, Kent W. Christopherson, II, PhD, Reem Karmali, MD, Melissa L. Larson, MD, Michelle Balla, Parameswaran Venugopal, MD

Blood (2013) 122 (21): 5232.

https://doi.org/10.1182/blood.V122.21.5232.5232

Published: 2013

Journal Articles

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Exhibit Altered Cytokine Protein Levels in Peripheral Blood Serum

Laura A Paganessi, MA, Robin R Frank, BS, Sucheta Jagan, MS, Reem Karmali, MD, Yan Li, Youping Deng, Cristina L Fhied, Jeffrey A Borgia, PhD, Melissa L Larson, M.D., Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Kent W Christopherson, II, PhD

Blood (2011) 118 (21): 2646.

https://doi.org/10.1182/blood.V118.21.2646.2646

Published: 2011

Journal Articles

CD20, CD22, CD23, but Not CD37 Expression on CD19 + B-Cells Is Altered by Exogenous Factors in a Sub-Population of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) Patients,

Robin R Frank, BS, Sucheta Jagan, MS, Laura A Paganessi, MA, Melissa L Larson, M.D., Reem Karmali, MD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Kent W Christopherson, II, PhD

Blood (2011) 118 (21): 3685.

https://doi.org/10.1182/blood.V118.21.3685.3685

Published: 2011

Journal Articles

Timed Sequential Induction Therapy with Cytarabine and Mitoxantrone In Acute Myeloid Leukemia (AML): A Well-Tolerated Regimen with High Response Rates In Older Patients and Transformed AML.

Sheena Sahota, M.D., Melissa L Larson, MD, Margaret C Keller, ACNP, Jamile M. Shammo, MD, Allison Zindell, Bharathi Muthusamy, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2010) 116 (21): 1068.

https://doi.org/10.1182/blood.V116.21.1068.1068

Published: 2010

Journal Articles

Favorable Outcome In Patients with Poor Prognosis Acute Myeloid Leukemia (AML) Using a 2-Day Induction Regimen Incorporating High Dose Cytarabine and Mitoxantrone.

Melissa L Larson, MD, Sheena Sahota, M.D., Margaret C Keller, ACNP, Bharathi Muthusamy, Allison Zindell, Jamile M. Shammo, MD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2010) 116 (21): 1069.

https://doi.org/10.1182/blood.V116.21.1069.1069

Published: 2010

Journal Articles

Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Reem Karmali, MD, Andrew Manson, Katherine Bueschel, MD, Kathryn Shell, Stephanie A. Gregory, MD, Teresa O'Brien, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD

Blood (2010) 116 (21): 3947.

https://doi.org/10.1182/blood.V116.21.3947.3947

Published: 2010

Journal Articles

Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate

Arlene Dawravoo, MD, Reem Karmali, MD, Amy Rizman, Stephanie A. Gregory, MD, Melissa L Larson, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD

Blood (2010) 116 (21): 4958.

https://doi.org/10.1182/blood.V116.21.4958.4958

Published: 2010

Journal Articles

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Andrew Manson, Reem Karmali, MD, Irene Dehghan-Paz, MD, Eduardo Braun, MD, Teresa O'Brien, Stephanie A. Gregory, MD, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD

Blood (2010) 116 (21): 4918.

https://doi.org/10.1182/blood.V116.21.4918.4918

Published: 2010

Journal Articles

Gain of CD20 Target Cell Surface Receptor Expression During Serum-Free Ex Vivo Culture of CD19 + CD5 + B-Cells In a Sub-Population of Early Stage (Rai 0/1) Chronic Lymphocytic Leukemia Patients

Robin Frank, BS, Hugo Jimenez, Sucheta Jagan, MS, Lydia Luy Tan, BS, Laura A Paganessi, MA, Melissa L Larson, MD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Kent W Christopherson, II, PhD

Blood (2010) 116 (21): 2000.

https://doi.org/10.1182/blood.V116.21.2000.2000

Published: 2010

NARROW

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

The Impact of Air Pollutants on a Chicagoland Cohort of Patients with Acute Myeloid Leukemia

A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic

Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML

Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Structural and Social Barriers to Survival in Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML)

The Impact of Non-Clinical Factors in Clinical Trial Enrollments of Patients with Hematologic Malignancies

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Exhibit Altered Cytokine Protein Levels in Peripheral Blood Serum

CD20, CD22, CD23, but Not CD37 Expression on CD19 + B-Cells Is Altered by Exogenous Factors in a Sub-Population of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) Patients,

Timed Sequential Induction Therapy with Cytarabine and Mitoxantrone In Acute Myeloid Leukemia (AML): A Well-Tolerated Regimen with High Response Rates In Older Patients and Transformed AML.

Favorable Outcome In Patients with Poor Prognosis Acute Myeloid Leukemia (AML) Using a 2-Day Induction Regimen Incorporating High Dose Cytarabine and Mitoxantrone.

Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Gain of CD20 Target Cell Surface Receptor Expression During Serum-Free Ex Vivo Culture of CD19 + CD5 + B-Cells In a Sub-Population of Early Stage (Rai 0/1) Chronic Lymphocytic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only